Male fertility diagnostics is undergoing a structural shift, driven by increasing demand for patient-friendly access combined with clinical-grade data. Sapyen has established a model that enables home-based sample collection while maintaining compatibility with laboratory-grade analysis, supporting integration into established fertility care pathways. Against this background, the MoU aims to assess how JUNO-Checked could complement and extend such diagnostic services by providing additional, clinically relevant insight into male fertility potential.

The intention of the MoU is to provide a structured framework under which the parties aim to evaluate a business model where Sapyen could take a leading role in commercial activities, supported by Spermosens' diagnostic technology. During the term of the MoU, the parties intend to assess commercial, operational and regulatory aspects relevant to a potential collaboration.

The MoU is non-binding and does not include any agreed commercial terms, exclusivity arrangements or commitments to enter into definitive agreements. Any potential collaboration remains subject to further evaluation and the execution of separate binding agreements.

Tore Duvold, CEO of Spermosens, comments: "We are highly impressed by Sapyen's patient-centric model and their unique SPX72™ technology, which provides the sample stability necessary for clinical-grade testing with home-based sample collection. This proprietary capability effectively bridges the gap between patient convenience and laboratory precision, making Sapyen an ideal partner as we evaluate scalable commercial pathways for JUNO-Checked. Their global platform offers a unique opportunity to bring our advanced diagnostic insights to a broader market."

Ashwin Ramachandran, CEO and Founder of Sapyen, comments: "JUNO-Checked addresses a fundamental and under-served biological dimension of male fertility that current diagnostic solutions largely overlook. We believe the technology has the potential to meaningfully augment existing diagnostic pathways and improve the quality of clinical decision-making. This Memorandum of Understanding signals a clear ambition to pursue category-defining advances in male fertility diagnostics, not marginal improvements at the edges."

About Spermosens AB
Spermosens AB is a biotechnology company focused on developing diagnostic solutions to improve fertility treatments. Based in Sweden, Spermosens specializes in the development of JUNO-Checked, a diagnostic method intended to provide clinically relevant insight into male fertility potential. The company's strategy is to demonstrate clinical value and pursue commercialization through partnerships and licensing agreements. Spermosens' shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com

About Sapyen Inc
Sapyen is a global male fertility diagnostics company with operations across the US, Europe, UK, and Australia. The company has developed the SPX72™ home sample collection kit, which preserves sperm viability for up to 72 hours, enabling samples collected at home to be analyzed in IVF-grade laboratories using clinical-standard techniques. Sapyen's approach combines patient convenience with rigorous laboratory-quality data, supporting clinics, laboratories and patients while maintaining diagnostic accuracy. The company is recognized for integrating innovative home-based diagnostics into established clinical workflows, helping to expand access to male fertility evaluation. For more information, see https://www.sapyen.co/

For further information, please contact:
Tore Duvold, CEO
E-mail: info@spermosens.com